Comparative Pharmacology
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus JANIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus JANIMINE.
CLOMIPRAMINE HYDROCHLORIDE vs JANIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake, with additional anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Imipramine inhibits the reuptake of norepinephrine and serotonin at nerve terminals, potentiating their neurotransmission. It also has anticholinergic and antihistaminergic effects.
Oral, initial 25 mg three times daily; increase gradually to 100-250 mg/day in divided doses; maximum 300 mg/day for severe conditions.
25-50 mg orally 2-4 times daily; maintenance 150 mg/day divided
None Documented
None Documented
Terminal elimination half-life of clomipramine is 19-37 hours (mean ~30 hours); active metabolite desmethylclomipramine has half-life of 54-77 hours. Steady-state achieved within 1-2 weeks.
5-15 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for steady state.
Renal: ~60% (as conjugated metabolites and unchanged drug); Fecal: ~30% (biliary excretion); 2-3% excreted unchanged in urine.
Primarily renal (70-80% as metabolites, 5% unchanged); biliary/fecal (20-30% as metabolites).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant